Please pay special attention to the accurate trend, and very accurate colored levels. The setup is very sensitive, do not get a position without SL. Be careful BEST MT
? Analysis: Bitcoin has completed its abc correction and formed an inverse head and shoulders pattern. The rapid price recovery after the recent dump indicates strong buying interest and the potential for a continuation of the bullish trend. Currently, Bitcoin may experience a small correction or directly break the key resistance at $102,200. If this level is broken, which aligns with the neckline of the inverse head and shoulders, it will signal the start of a new upward wave, potentially driving the price toward higher targets. ? Trade Setup: Trade Type: Long (Buy) Entry: $102,200 Target: $112,000 Stop Loss: $98,500 ⚡ Notes: Wait for confirmation of the resistance break before entering. Apply proper risk management and adjust trade size accordingly.
I found another small cap that has a great looking chart over the past several weeks. This project works on a multi chain AI compute layer. This application focuses on blockchain based business applications. I care mostly about the chart here and the fact this is on base. We are getting a nice reset of the stochastic on the daily with a huge stall in price action. The prior two pumps has 7 day halts, will we see another? This token is about 10 million market cap, I predict we will see a very quick ten x on this especially as it becomes more obvious that this is on uniswap and equalizer.
The picture says it all, looks like a giant IHS pattern, and just break out. Worth a try.
Still not overbought, high greed levels, I expect a small hike up, some bearish divergence, then a continuation of bullish price action.
**Bitcoin Yellow Line Price Prediction Analysis** This chart presents a speculative trajectory for Bitcoin's price based on historical patterns around the **2024 Halving** (April 15, 2024) and the **U.S. Elections** (November 2024): 1. **Pre-Halving Accumulation:** ✅ - Bitcoin consolidates with steady upward momentum leading into the Halving event, respecting long-term support levels and gradually breaking key resistance zones. 2. **Post-Halving Rally:** ✅ - Following the Halving, Bitcoin experiences a sharp bullish rally, historically driven by reduced supply and increased demand, potentially targeting the $100,000+ range. 3. **Volatility Around U.S. Elections:** ✅ - Leading up to and following the U.S. Elections, significant market volatility is expected. Peaks and corrections highlight possible short-term speculative behavior, with price briefly reaching higher Fibonacci extensions near $160,000. 4. **Correction and Consolidation Phase:** - After reaching speculative highs, Bitcoin retraces to test lower support levels (~$70,000–$80,000) before stabilizing into a broader accumulation phase. 5. **End of 2025 and Beyond:** - The yellow line suggests another upward trajectory post-consolidation, marking the beginning of a new cycle. **Key Notes:** - The yellow line follows historical Bitcoin post-Halving behavior but incorporates macroeconomic events like elections that could amplify volatility. - This is a speculative analysis based on past patterns and major events; market conditions and external factors could heavily influence outcomes.
Trend and rotation setups. Potential longs on high volume.
I received a request to update my BTC.D outlook, so here it is: We crossed my green support line much sooner than expected, prompting me to update the simple line into a more detailed channel. While this might suggest we’ve broken the support, I still believe we’re in an uptrend overall. I’m watching for a bounce off the 25% dotted line within the channel, which sits around 54% BTC dominance. From there, I anticipate a new push higher as BTC targets $150K or more in Q1. However, BTC.D going down doesn’t necessarily mean bad news. It simply reflects more liquidity moving into altcoins rather than BTC. Theoretically, BTC’s price could rise even as BTC.D declines. Looking at pairs like Others/BTC or charts like Total10, it’s clear that altcoins are poised to outperform BTC for now, which would naturally cause BTC.D to drop. That said, let’s not get ahead of ourselves. As long as we see a reaction at 54% BTC.D and remain within this channel, we can stay confident in the market’s structure. It’s important to remain calm and avoid becoming so heavily invested that it clouds your judgment. This cycle’s sentiment has been quite unusual. Many expected a left-translated cycle, with a BTC cycle top before November 2024. As we’ve seen, this wasn’t the case, and BTC continues to climb. Similarly, many now anticipate a top in January, February, or March. In my view, it’s unproductive to speculate too heavily or to cling too tightly to specific narratives. Keep in mind that many influencers earn their living through social media, and bold predictions often gain traction. However, markets and history tend to rhyme, which is why the phrase “this time is different” is often a meme in trading circles. Best regards, God bless
#doge CRYPTOCAP:DOGE price has formed a running wedge and aiming the red box upside in short term. Not financial advice.
VTV Therapeutics (VKTX) is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat metabolic diseases. The company primarily targets areas such as non-alcoholic steatohepatitis (NASH), type 2 diabetes, and other metabolic disorders. Here's an in-depth look at the company, its position in the industry, unique aspects, developments, and market potential. As we can see from the above chart, Viking has recently broken the upper channel resistance level and its currently gone in for the re-test to confirm this level as support. However, it appears to be inching back within the channel, signalling a potential break down in price. Industry Overview: Metabolic Disease Therapies The metabolic disease market is a rapidly growing sector, driven by the increasing prevalence of conditions like type 2 diabetes, obesity, NASH, and other liver diseases. The demand for effective treatments in these areas is rising as the global population experiences higher rates of these chronic conditions. NASH, for instance, is a significant focus of research because it can lead to liver cirrhosis and liver cancer, and there are currently limited approved treatments for it. The diabetes and obesity market is also substantial, with new treatments focusing on insulin resistance, fat metabolism, and weight management in high demand. Unique Aspects of VTV Therapeutics (VKTX) 1. Selective Receptor Modulators: [/i ] One of the company’s key differentiators is its use of selective receptor modulators (SRMs), which are designed to specifically target receptors involved in metabolic diseases. This approach allows for potentially more effective treatments with fewer side effects than traditional therapies. 2. Lead Drug Candidate - VTX-800: VTV’s lead candidate is VTX-800, a small molecule selective FFAR4 receptor modulator. This drug is being developed to treat NASH and type 2 diabetes, targeting the free fatty acid receptor 4 (FFAR4), which plays a crucial role in metabolism and insulin sensitivity. In preclinical and early clinical trials, VTX-800 has demonstrated potential for improving both liver function and insulin resistance in patients. 3. Strong Pipeline: In addition to VTX-800, VTV Therapeutics has other promising compounds in its pipeline targeting type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Their approach leverages cutting-edge metabolic biology to address large, underserved markets. 4. Collaborations: The company has also entered into various collaborations with larger biopharmaceutical companies to enhance its research and development capabilities. These partnerships help strengthen its position in the competitive market for metabolic disease therapies. Recent Developments and Trials Phase 2 Clinical Trials: VTX-800 is currently in Phase 2 clinical trials for NASH and type 2 diabetes. The drug has shown promising preclinical results in both liver function and glycemic control, positioning it as a potential breakthrough in these areas. NASH Pipeline: VTV is also pursuing additional treatments for NASH, a field where there is intense competition due to the lack of approved therapies and the growing demand for effective solutions. Type 2 Diabetes Research: Their research on type 2 diabetes involves addressing insulin resistance, a major contributor to the disease. This is a massive market, with increasing incidence globally, creating significant potential for therapies that can effectively manage or reverse the condition. Current Market Cap and Financials As of December 2024, VTV Therapeutics' market cap is approximately $225 million. The company has seen fluctuating stock prices based on clinical trial results and investor sentiment regarding its drug candidates. The small market cap reflects its current stage as a clinical-stage biotech firm, with significant risk and potential rewards as it moves through its clinical trial phases. Potential Future Market Cap The future market cap of VTV Therapeutics will heavily depend on the successful progression and approval of its key drug candidates. If VTX-800 proves to be effective in Phase 3 trials for NASH or type 2 diabetes, the company’s market cap could see a substantial increase, potentially in the $1-2 billion range or higher, similar to other biotech firms that have brought successful metabolic disease drugs to market. 1. NASH Market: The NASH market alone is expected to grow to more than $20 billion by 2025, driven by rising prevalence and lack of treatment options. If VTX-800 is approved for NASH, VTV Therapeutics could capture a significant share of this market, significantly boosting its valuation. 2. Type 2 Diabetes and Obesity : As the prevalence of type 2 diabetes and obesity continues to rise globally, therapies targeting insulin resistance and metabolic function are in high demand. Successful clinical results in these areas could substantially increase VTV Therapeutics’ market cap. Conclusion VTV Therapeutics (VKTX) is a promising player in the metabolic disease space with its innovative approach to targeting diseases like NASH and type 2 diabetes. The company’s progress in clinical trials, particularly with VTX-800, positions it to potentially disrupt the metabolic disease treatment market. While its current market cap reflects the risks associated with being a clinical-stage biotech, the company has significant upside potential, particularly if its leading drug candidate achieves clinical success and gains regulatory